HIGHLIGHTS
- who: Intermittent Atrioventricular Block following and colleagues from the Department of Neurology, Athens National and Kapodistrian University, "Aeginition" Hospital, Athens, Greece have published the paper: Case Report Intermittent Atrioventricular Block following Fingolimod Initiation, in the Journal: (JOURNAL) of 13/04/2014
- what: The authors report a female MS patient who developed reversible symptomatic Weckenbach type of AVB after the first two doses of fingolimod and discuss the underlying mechanisms possibly involved in the pathophysiology of this adverse event.
SUMMARY
Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator used for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.